302 related articles for article (PubMed ID: 26319783)
1. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
[TBL] [Abstract][Full Text] [Related]
2. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
3. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
[TBL] [Abstract][Full Text] [Related]
5. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
[TBL] [Abstract][Full Text] [Related]
7. Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia.
Brunetti C; Anelli L; Zagaria A; Minervini A; Minervini CF; Casieri P; Coccaro N; Cumbo C; Tota G; Impera L; Orsini P; Specchia G; Albano F
J Mol Diagn; 2017 May; 19(3):437-444. PubMed ID: 28268092
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
[TBL] [Abstract][Full Text] [Related]
10. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
[TBL] [Abstract][Full Text] [Related]
12. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
14. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
[TBL] [Abstract][Full Text] [Related]
15. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
16. Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia.
Coccaro N; Anelli L; Zagaria A; Casieri P; Tota G; Orsini P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Carluccio P; Brunetti C; Specchia G; Albano F
J Mol Diagn; 2018 Jul; 20(4):474-482. PubMed ID: 29625246
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas.
Kato H; Yamamoto K; Oki Y; Ine S; Taji H; Chihara D; Kagami Y; Seto M; Morishima Y
Leukemia; 2012 Jan; 26(1):166-9. PubMed ID: 21818114
[No Abstract] [Full Text] [Related]
18. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
[TBL] [Abstract][Full Text] [Related]
19. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
20. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]